How Medical Robot Cost Actually Breaks Down
Medical robot price is quoted as a capital number, but hospitals spend more over the useful life on the recurring line items. Intuitive Surgical (da Vinci Xi, X, SP, and the newer da Vinci 5), CMR Surgical (Versius), Zimmer Biomet (Rosa Knee and Rosa Brain), Stryker (Mako), and Medtronic (Hugo RAS) all sell into that same three-part structure: capital, disposables, and service.
The Bot Scout price-a-robot rule is that the capital number is the smallest of the three over a five-year window in a busy program. A soft-tissue robot that runs 400 cases a year at roughly $2,000 in disposables per case spends $800,000 a year on consumables alone, which is on the order of the arm itself. Service contracts typically add another 10 to 12 percent of capital per year after the first year.
Public financials confirm the pattern. In its quarterly filings, Intuitive reports instruments-and-accessories and services revenue that together dwarf systems revenue, which is exactly what the recurring-cost line looks like from the manufacturer side.
| System (maker) | Primary use | Reported capital range (USD) | Per-procedure disposables (USD) | Annual service contract |
|---|---|---|---|---|
| da Vinci Xi (Intuitive Surgical) | Multi-quadrant soft-tissue: urology, gyn, general, thoracic | ~$1.5M–$2.5M new; ~$0.7M–$1.2M refurbished/older gen | ~$1,500–$3,500 (EndoWrist instruments have per-use counters plus accessories) | ~$150K–$190K after year one |
| da Vinci SP (Intuitive Surgical) | Single-port urology, transoral, select colorectal | ~$2.0M–$2.5M | ~$1,800–$3,500 | ~$150K–$200K |
| Versius (CMR Surgical) | Modular multi-arm soft-tissue, often leased/pay-per-use | Capital ~$1.0M–$1.5M or usage-based pricing | ~$1,200–$2,500 | Bundled in usage model or ~$120K–$170K |
| Hugo RAS (Medtronic) | Modular soft-tissue: urology, gyn, general (regional availability) | ~$1.2M–$1.9M | ~$1,500–$3,000 | ~$120K–$180K |
| Rosa Knee / Rosa Brain (Zimmer Biomet) | Ortho (TKA) and stereotactic neurosurgery | ~$0.6M–$1.0M (Knee); ~$0.8M–$1.2M (Brain) | ~$800–$1,500 in single-use ortho consumables; imaging/planning fees for Brain | ~$70K–$120K |
| Mako (Stryker) | Ortho: partial and total knee, total hip | ~$1.0M–$1.25M | ~$1,200–$2,000 in Mako-specific single-use instruments (plus implant) | ~$100K–$150K |
Capital, Disposables, and Service: What Each Line Really Buys
Capital price buys the console, the patient cart or arms, the vision cart, and initial training. It does not usually include the OR build-out, the imaging or navigation stack a system depends on, or the initial disposable inventory a hospital has to stock to run a real schedule.
Disposables are the line that surprises finance. Intuitive publishes EndoWrist instrument lives (often 10 to 18 uses depending on the tool), after which the instrument locks out and is replaced — this is documented in Intuitive's FDA 510(k) submissions and instrument IFUs. Mako and Rosa Knee use single-use arrays and cutting guides per case. Versius and Hugo use per-case instrument kits with their own use limits.
Service contracts cover preventive maintenance, software updates, and rapid parts replacement — a stopped robotic OR is expensive, so the contract is really uptime insurance. Most hospitals negotiate year-one service into the capital deal and pay separately from year two onward at roughly 10 to 12 percent of system list per year.
- Ask for a five-year total cost of ownership at your projected case volume, not a capital quote.
- Confirm which instruments have per-use counters and model annual replacement against your case mix.
- Price the OR build (boom, monitors, imaging integration) as part of the robot, not the room.
- Model uptime penalties: what a canceled robotic day costs you if service response slips.
- Compare purchase, lease, and pay-per-use (Versius and some Hugo deals) at your real volume.
Does Insurance Cover Robotic Surgery?
In the United States, payers generally cover the underlying procedure (a prostatectomy, hysterectomy, partial nephrectomy, knee replacement) rather than paying separately because a robot was used. CMS coverage databases and most commercial medical policies treat robotic-assisted approaches as one of several accepted surgical techniques when the procedure itself is medically necessary and covered.
This means patient out-of-pocket cost is usually driven by plan design (deductible, coinsurance, in-network status, facility fee), not by the presence of the robot. Hospitals absorb the higher per-case cost of robotic surgery through the same DRG or bundled payment as the open or laparoscopic version — a dynamic examined in peer-reviewed hospital-economics work such as the JAMA Network Open analysis of robotic vs laparoscopic general surgery cost.
Advertised coverage nuances do exist. Some payer policies name specific procedures (for example, robotic-assisted partial nephrectomy or robotic-assisted radical prostatectomy) as covered and others as investigational. UnitedHealthcare, Aetna, and Anthem each publish their own medical policies, and they change; a patient should confirm their specific plan and CPT code with the payer before scheduling.
This page is informational and is not medical or financial advice. Coverage decisions belong to the patient, the surgeon, and the payer.
What Drives the Business Case at a Hospital
The published literature is mixed on whether robotic surgery is cheaper per case than open or laparoscopic alternatives, and the answer depends on the procedure and the program's maturity. Reviews in Annals of Surgery and JAMA Surgery have flagged higher supply costs for robotic approaches, offset in some studies by shorter length of stay and lower complication rates for specific procedures.
The internal business case usually rests on three things: case volume high enough to spread capital and service across many cases, a service line that would otherwise send the procedure elsewhere (a retention argument), and OR throughput that does not collapse because of docking and turnover times. Programs that miss any of the three tend to underrun their pro forma.
On the ortho side, Mako and Rosa Knee tie tightly to implant systems, so the capital cost is negotiated inside a broader implant deal. That is one reason ortho robot pricing is harder to compare head-to-head than soft-tissue robots.
How to Read a Robotic-Surgery Quote
Vendor quotes are structured to make the capital number comparable and the recurring numbers less so. Ask every vendor to present the same five-year model at your projected case volume, with instrument and accessory pricing per case, service contract terms after year one, and any minimum-volume clauses if a pay-per-use option is on the table.
Refurbished and last-generation systems can change the math. Refurbished da Vinci Xi units, older Rosa consoles, and end-of-lease Mako systems trade at a significant discount to new list. The tradeoff is a shorter remaining service window and, in some cases, no path to the newest software or instrument families.
The last question worth asking is what happens at end of life. Manufacturers move software support to new generations on their own schedule, and a system that is no longer supported becomes a very expensive paperweight. Confirm in writing how long the model you are quoted will be supported.
- Request a five-year TCO in the same format from every vendor.
- Get instrument and accessory pricing per procedure type, not a blended number.
- Nail down service response times and penalties, not just the annual fee.
- Ask about refurbished, leased, and pay-per-use alternatives at your volume.
- Get written end-of-support commitments before signing capital.
Bottom Line
Medical robot cost is capital, disposables, and service — and in a busy program the recurring lines outrun the capital number within a few years. Insurance coverage for the patient tracks the procedure, not the robot, so patient out-of-pocket cost depends on the plan and the CPT code, not the technology.
Model five-year total cost of ownership at your real case volume before choosing a robotic surgery system.
FAQs
How much does a da Vinci surgical robot cost?
Publicly reported figures for a new da Vinci Xi place capital cost in the range of roughly $1.5M to $2.5M, with refurbished or older-generation units reported closer to $0.7M to $1.2M. Per-procedure instruments and accessories add roughly $1,500 to $3,500 per case, and annual service contracts typically run about 10 to 12 percent of system list price after year one.
Does health insurance cover robotic surgery?
In the U.S., insurance coverage generally follows the underlying procedure rather than the surgical technique. If a hysterectomy, prostatectomy, or knee replacement is medically necessary and covered under the patient's plan, a robotic-assisted approach is usually treated the same as the open or laparoscopic version. Some payer policies name specific procedures as covered or investigational, so patients should confirm the specific CPT code with their plan.
Which is cheaper for a hospital: Mako or Rosa?
Reported capital pricing puts Mako in roughly the $1.0M to $1.25M range and Rosa Knee in roughly the $0.6M to $1.0M range, but both are usually negotiated inside a broader implant or capital deal, which changes the effective price. The per-case disposable and service picture matters at least as much as the sticker.
Are refurbished surgical robots safe to buy?
Refurbished systems from the original manufacturer or an authorized third party can be a legitimate way to lower capital cost, especially for older-generation da Vinci and Rosa units. The hospital should confirm remaining service life, software support timeline, and compatibility with current instrument families before signing.
Why are robotic surgery disposables so expensive?
Most robotic instruments carry per-use counters set by the manufacturer to bound reuse and preserve mechanical performance. Once the count is reached the instrument locks out and must be replaced. This model is documented in FDA 510(k) submissions and instructions for use, and it is a deliberate part of the recurring-revenue design of these systems.